92539-14-5

Basic information

• Product Name: 1-(4-fluorobenzyl)piperidin-4-amine(SALTDATA: 1.98HCl 0.75H2O)
• Synonyms: 1-(4-fluorobenzyl)piperidin-4-amine(SALTDATA: 1.98HCl 0.75H2O);1-[(4-fluorophenyl)methyl]piperidin-4-amine
• CAS NO: 92539-14-5
• Molecular Formula: C₁₂H₁₇FN₂
• Molecular Weight: 208.2751832
• Mol File: 92539-14-5.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 286.4±35.0 °C(Predicted)
• Appearance: /
• Density: 1 +-.0.06 g/cm3(Predicted)
• PKA: 10.11±0.20(Predicted)
• CAS DataBase Reference: 1-(4-fluorobenzyl)piperidin-4-amine(SALTDATA: 1.98HCl 0.75H2O)(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-fluorobenzyl)piperidin-4-amine(SALTDATA: 1.98HCl 0.75H2O)(92539-14-5)
• EPA Substance Registry System: 1-(4-fluorobenzyl)piperidin-4-amine(SALTDATA: 1.98HCl 0.75H2O)(92539-14-5)

Safety Data

• Hazardous Substances Data: 92539-14-5(Hazardous Substances Data)

Usage

General Description

1-(4-fluorobenzyl)piperidin-4-amine, also known as SALTDATA, is a chemical compound with the molecular formula C11H14FN3 and a molecular weight of 206.25 g/mol. It exists in the form of a hydrochloride salt with a stoichiometry of 1.98HCl 0.75H2O. 1-(4-fluorobenzyl)piperidin-4-amine(SALTDATA: 1.98HCl 0.75H2O) is a piperidine derivative with a fluoro-substituted benzyl group, and it is commonly used in research and pharmaceutical applications. The hydrochloride salt form of SALTDATA enhances its stability and solubility, making it suitable for various medical and technical uses. It is important to handle and store this compound with care, following all safety guidelines and regulations.

Upstream product

• 50541-93-0 4-amino-1-benzylpiperidine 
• 73889-19-7 tert-butyl (1-benzylpiperidin-4-yl)carbamate 
• 459-57-4 4-fluorobenzaldehyde 
• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 
• 358748-21-7 tert-butyl (1-(4-fluorobenzyl)piperidin-4-yl)carbamate 
• 352-11-4 1-chloromethyl-4-fluorobenzene 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 380424-12-4 1-(4-fluoro-benzyl)-piperidine-4-carboxylic acid amide 

Downstream Products

• 939795-72-9 C₁₉H₁₉N₄O₂SF 
• 939795-74-1 C₁₉H₁₉N₄O₂SF 
• 1356125-36-4 N-[1-(4-fluorobenzyl)piperidin-4-yl]-4-[[(2-(methylamino)-6-methylquinazolin-4-yl)amino]methyl]benzamide 
• 1356125-37-5 N-[1-(4-fluorobenzyl)piperidin-4-yl]-4-[[(2-(propylamino)-6-methylquinazolin-4-yl)amino]methyl]benzamide 
• 1356125-38-6 N-[1-(4-fluorobenzyl)piperidin-4-yl]-4-[[(2-(dimethylamino)-6-methylquinazolin-4-yl)amino]methyl]benzamide 
• 1356125-40-0 (+/-)-N-[1-(4-fluorobenzyl)piperidin-4-yl]-4-[[(2-(3-methylpiperazin-1-yl)-6-methylquinazolin-4-yl)amino]methyl]benzamide 
• 1229829-20-2 6-Chloro-2-[1-(4-fluoro-benzyl)-piperidin-4-ylcarbamoyl]-7-methoxy-2, 3-dihydro-benzo[1,4]oxazine-4-carboxylic acid tert-butyl ester 

Relevant articles and documents

Design and development of novel thiazole-sulfonamide derivatives as a protective agent against diabetic cataract in Wistar rats via inhibition of aldose reductase

In recent years, ALR2 (aldose reductase) inhibitors have attracted attention for their effective ability to reduce the progression of diabetes-associated cataracts. Therefore, in the present article, we intended to develop novel thiazole-sulfonamide hybrids as a potent inhibitor of ALR2. These molecules significantly inhibited the ALR2 level in the rat lenses homogenate, where the most potent compound 7b showed activity comparable to sorbinil as standard. In Wistar rats, compound 7b improved the insulin level and body weight of the experimental animal together with a reduction in the glucose output. Compound 7b showed a significant reduction in the expression of ALR2 in rat lenses in western blot analysis.

N-substituted piperidine amide derivative and application thereof

The invention discloses an N-substituted piperidine amide derivative and application thereof and particularly relates to a series of novel N-substituted piperidine amide derivatives and medicine compositions comprising same. The compounds can be used as a

Rational Design and Multibiological Profiling of Novel Donepezil-Trolox Hybrids against Alzheimer's Disease, with Cholinergic, Antioxidant, Neuroprotective, and Cognition Enhancing Properties

A novel series of donepezil-trolox hybrids were designed, synthesized, and evaluated as multifunctional ligands against Alzheimer's disease (AD). Biological assays showed that these derivatives possessed moderate to good inhibitory activities against acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B) as well as remarkable antioxidant effects. The optimal compound 6d exhibited balanced functions with good inhibition against hAChE (IC50 = 0.54 μM) and hMAO-B (IC50 = 4.3 μM), significant antioxidant activity (41.33 μM IC50 by DPPH method, 1.72 and 1.79 trolox equivalent by ABTS and ORAC methods), excellent copper chelation, and Aβ1-42 aggregation inhibition effect. Furthermore, cellular tests indicated that 6d has very low toxicity and is capable of combating oxidative toxin (H2O2, rotenone, and oligomycin-A) induced neurotoxicity. Most importantly, oral administration of 6d demonstrated notable improvements on cognition and spatial memory against scopolamine-induced acute memory deficit as well as d-galactose (d-gal) and AlCl3 induced chronic oxidative stress in a mouse model without acute toxicity and hepatotoxicity. In summary, both in vitro and in vivo results suggested that 6d is a valuable candidate for the development of a safe and effective anti-Alzheimer's drug.